Results 1 to 10 of about 1,008 (67)

Anti-SARS-CoV-2 spike IgG following injection of the third dose vaccine: A systematic review with meta-analysis of heterologous versus homologous vaccination

Frontiers in Public Health, 2023
BackgroundThe mass vaccination is a key strategy to prevent and control the coronavirus disease 2019 (COVID-19) pandemic. Today, several different types of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed ...
Fahimeh Attarian, Mojadadi Mohammad Shafi, Seyed Alireza Javadinia   +2 more
exaly   +3 more sources

Comparing Heterologous and Homologous COVID-19 Vaccination: A Longitudinal Study of Antibody Decay

Viruses, 2023
The humoral response after vaccination was evaluated in 1248 individuals who received different COVID-19 vaccine schedules. The study compared subjects primed with adenoviral ChAdOx1-S (ChAd) and boosted with BNT162b2 (BNT) mRNA vaccines (ChAd/BNT) to ...
Aurora Diotallevi, Anna Casabianca, Mauro Magnani   +2 more
exaly   +3 more sources

Exploring Prime-Boost Vaccination Regimens with Different H1N1 Swine Influenza A Virus Strains and Vaccine Platforms

Vaccines, 2022
In a previous vaccination study in pigs, heterologous prime-boost vaccination with whole-inactivated H1N1 virus vaccines (WIV) induced superior antibody responses and protection compared to homologous prime-boost vaccination.
Anna Parys, Elien Vandoorn, Koen Chiers, Katharina Passvogel, Walter Fuchs, Thomas C. Mettenleiter, Kristien Van Reeth   +6 more
doaj   +1 more source

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination

Journal of the Formosan Medical Association, 2022
Background/Purpose: Efficacy and safety data of heterologous prime-boost vaccination against SARS-CoV-2 remains limited. Methods: We recruited adult volunteers for homologous or heterologous prime-boost vaccinations with adenoviral (ChAdOx1, AstraZeneca)
Wang-Huei Sheng, Sui-Yuan Chang, Pin-Hung Lin, Ming-Ju Hsieh, Hao-Hsiang Chang, Chien-Yu Cheng, Hung-Chih Yang, Ching-Fu Pan, Si-Man Ieong, Tai-Ling Chao, Jang-Pin Chen, Shu-Hsing Cheng, Shan-Chwen Chang   +12 more
doaj   +1 more source

Heterologous vaccination (ChAdOx1 and BNT162b2) induces a better immune response against the omicron variant than homologous vaccination

Journal of Infection and Public Health, 2023
Background: The ongoing COVID-19 pandemic has seen the emergence of numerous novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus.
Jaeeun Yoo, Younjeong Kim, Yu mi Cha, Jaewoong Lee, Yeon Jeong Jeong, Si-Hyun Kim, Lisa L. Maragakis, Seungok Lee   +7 more
doaj   +1 more source

Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults

Scientific Reports, 2023
In this single-center observational study with 1,206 participants, we prospectively evaluated SARS-CoV-2-antibodies (anti-S RBD) and vaccine-related adverse drug reactions (ADR) after basic and booster immunization with BNT162b2- and ChAdOx1-S-vaccines ...
Simon Dedroogh, Sven Schmiedl, Petra A. Thürmann, Katharina Graf, Sebastian Appelbaum, Reinhard Koß, Christian Theis, Zewarudin Zia, Jürgen Tebbenjohanns, Serge C. Thal, Michael Dedroogh   +10 more
doaj   +1 more source

Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity

Frontiers in Immunology, 2023
Currently available COVID-19 vaccines include inactivated virus, live attenuated virus, mRNA-based, viral vectored and adjuvanted protein-subunit-based vaccines.
Larissa Henze, Larissa Henze, Julian Braun, Julian Braun, Lil Meyer-Arndt, Lil Meyer-Arndt, Lil Meyer-Arndt, Lil Meyer-Arndt, Karsten Jürchott, Karsten Jürchott, Maike Schlotz, Janine Michel, Marica Grossegesse, Maike Mangold, Maike Mangold, Manuela Dingeldey, Manuela Dingeldey, Beate Kruse, Beate Kruse, Pavlo Holenya, Norbert Mages, Norbert Mages, Norbert Mages, Ulf Reimer, Maren Eckey, Karsten Schnatbaum, Holger Wenschuh, Bernd Timmermann, Florian Klein, Florian Klein, Florian Klein, Andreas Nitsche, Claudia Giesecke-Thiel, Lucie Loyal, Lucie Loyal, Andreas Thiel, Andreas Thiel   +36 more
doaj   +1 more source

Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines

Vaccines, 2022
Heterologous primary immunization against SARS-CoV-2 is part of applied recommendations. However, little is known about duration of immune responses after heterologous vaccine regimens.
Ulrika Marking, Sebastian Havervall, Nina Greilert-Norin, Henry Ng, Kim Blom, Peter Nilsson, Mia Phillipson, Sophia Hober, Charlotta Nilsson, Sara Mangsbo, Wanda Christ, Jonas Klingström, Max Gordon, Mikael Åberg, Charlotte Thålin   +14 more
doaj   +1 more source

Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial

Frontiers in Immunology, 2023
Background/PurposeOptimizing vaccine efficacy is of particular concern in patients undergoing hematopoietic stem cell transplantation (HSCT), which mainly have an inadequate immune response to primary SARS-CoV-2 vaccination.
Leyla Sharifi Aliabadi, Manoochehr Karami, Manoochehr Karami, Maryam Barkhordar, Seyed Saeed Hashemi Nazari, Amir Kavousi, Mohammad Ahmadvand, Mohammad Vaezi, Mohammad Vaezi   +8 more
doaj   +1 more source

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review

Infectious Diseases of Poverty, 2022
Background Heterologous prime-boost with ChAdOx1 nCoV-19 vector vaccine (ChAd) and a messenger RNA vaccine (BNT or mRNA-1273) has been widely facilitating mass coronavirus disease 2019 (COVID-19) immunisation.
Jingjing Lv, Hui Wu, Junjie Xu, Jiaye Liu   +3 more
doaj   +1 more source